Drug Application
Observation on the effects of digglitazone and acarbose in combination treatment with metformin for type 2 diabetes mellitus with obesity
Wen Conghui, Yang Yingjun, Xu Lingyu
Published 2020-01-25
Cite as Chin J Pract Med, 2020,47(02): 110-113. DOI: 10.3760/cma.j.issn.1674-4756.2020.02.032
Abstract
ObjectiveTo explore the effects of digglitazone and acarbose in combination treament with metformin for type 2 diabetes mellitus (T2MD) complicated with obesity.
MethodsA total of 110 T2MD patients with obesity in Zhengzhou Seventh People’s Hospital from May 2018 to December 2018 were enrolled. They were divided into group A and group B by random number table method, with 55 cases in each group. Both groups were given basic treatment plans for T2MD. On this basis, group A was given dapagliflozin combined with metformin, while group B was given acarbose combined with metformin. The blood glucose indexes, insulin indexes, blood lipid indexes, body mass index (BMI) and occurrence of adverse reactions were compared between the two groups.
ResultsAfter treatment, blood glucose indexes such as fasting plasma glucose (FPG), postprandial 2 h plasma glucose (2hPG), glycosylated hemoglobin (HbA1c) in group A were lower than those in group B (P<0.05). After treatment, there was no significant difference in insulin indexes such as fasting insulin (FINS) and postprandial 2 h insulin (2hINS) between the two groups (P>0.05). After treatment, contents of total cholesterol (TC), hyperlipidemia (TG) and low-density lipoprotein cholesterol (LDL-C), and BMI index in group A were lower than those in group B, while content of high-density lipoprotein cholesterol (HDL-C)was higher than that in group B (P<0.05). There was no significant difference in incidence of adverse reactions during treatment between the two groups (P>0.05).
ConclusionsDapagliflozin combined with metformin is more effective than acarbose combined with metformin in terms of improving blood lipid levels and reducing weight of patients.
Key words:
Diabetes mellitus, type 2; Obesity; Dapagliflozin; Acarbose
Contributor Information
Wen Conghui
Department of Endocrinology and Geriatrics, Zhengzhou Seventh People’s Hospital, Zhengzhou 450016, China
Yang Yingjun
Department of Endocrinology and Geriatrics, Zhengzhou Seventh People’s Hospital, Zhengzhou 450016, China
Xu Lingyu
Department of Endocrinology, Zhengzhou Central Hospital, Zhengzhou 450000, China
